JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Olema Pharmaceuticals (NASDAQ:OLMA) but lowers the price target from $33 to $31.
August 08, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Olema Pharmaceuticals but lowers the price target from $33 to $31.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100